super responder tirzepatide GLP-1 Hyper-Responders: The Good, The Bad, and The Truth | Dr. Dan Tirzepatide | PeterMD
Description
Orforglipron (Foundayo) approved April 2026, the first once-daily GLP-1 pill with no food or water restrictions
No significant differences in PVS characteristics were found between those who did or did not exhibit symptoms of SANS
Two to three resistance training sessions per week is a commonly recommended baseline for anyone on GLP-1 therapy, specifically to signal the body to hold onto muscle even as fat mass drops
Behavioral factors amplify medication stalls
doi: 10.1038/s41586-024-07685-6 77 LuZChanSWTuLNganMPRuddJA
Tirzepatide's weight-loss approval is from 2023
